Edition:
India

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

10.80USD
20 Sep 2019
Change (% chg)

$-0.08 (-0.74%)
Prev Close
$10.88
Open
$10.88
Day's High
$10.91
Day's Low
$10.48
Volume
140,421
Avg. Vol
52,065
52-wk High
$17.80
52-wk Low
$9.23

Auchincloss, Thomas 

Mr. Thomas G. Auchincloss Jr., is an Independent Director of Concert Pharmaceuticals Inc. Mr. Auchincloss is the Director of the Company. effective December 9, 2014. Since October 2013, Mr. Auchincloss has served as Managing Partner at Counterpoint Trading Company, LLC, a private investment firm. From August 2007 through September 2013, Mr. Auchincloss was self-employed in private investing. From May 2005 to August 2007, Mr. Auchincloss worked as Chief Financial Officer of Metabolix, Inc., a public biomaterials company. Prior to that, Mr. Auchincloss served as a consultant with Metabolix, from April 2002 to May 2005, providing business development, financial and strategic consulting services. From 1994 to 2001, Mr. Auchincloss served in a variety of positions at Vertex Pharmaceuticals Incorporated, most recently as Vice President, Finance and Treasurer. Mr. Auchincloss received a B.S. in Business Administration from Babson College and an M.B.A. in Finance from the Wharton School. We believe that Mr. Auchincloss’ financial and industry experience, including his experience as the chief financial officer of a publicly traded biomaterials company, make him a key contributor to our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 71,865
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 133,748
Fiscal Year Total, USD 205,613

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

205,613

Roger Tung

4,607,850

Marc Becker

2,450,530

Nancy Stuart

1,908,030

James Cassella

1,960,240

Thomas Auchincloss

205,613
As Of  31 Dec 2018